Hormone Replacement Therapy and Breast Cancer: What Patients Need to Know

Hormone Replacement Therapy (HRT) can provide meaningful relief for women experiencing menopausal symptoms such as hot flashes, night sweats, mood changes and sleep disruption. For many patients, however, questions about breast cancer risk often create uncertainty about whether HRT is the right choice.

The reality is nuanced: some forms of HRT may slightly increase breast cancer risk, while others may have little to no impact depending on the type of therapy, duration of use and a patient’s individual health history. What’s most important is that women have informed conversations with their healthcare providers—and continue following recommended breast cancer screening guidelines.

Is There a Correlation Between HRT and Breast Cancer?

Research over the last two decades has shown that combined hormone therapy containing both estrogen and progestin may slightly increase breast cancer risk when used for several years. Estrogen-only therapy does not appear to confer an increased risk of breast cancer, but is typically only used in women who have had a hysterectomy.¹

Experts also note that the overall increase in risk for many women remains relatively small and should be weighed alongside the quality-of-life benefits HRT may provide.¹

“Every patient’s situation is unique. Hormone replacement therapy is not a one-size-fits-all decision. Women should have open conversations with their provider about their personal risk factors, symptoms and family history to determine the best path forward.”

— Dr. Jennifer Szurgot, Primary Care Physician and President, Pinehurst Medical Clinic

Risk Factors to Consider

Not all hormone therapies are the same. Risk can vary based on:

• Whether therapy contains estrogen alone or estrogen plus progestin
• How long therapy is used
• Age at initiation
• Personal and family history of breast cancer
• Breast density and other risk factors
• Dose and method of delivery (pill, cream, patch)

In addition, some women taking HRT may experience increased breast density, which can make mammograms more difficult to interpret.³

Why Breast Cancer Screening Matters

Whether a patient chooses to pursue HRT or not, routine breast cancer screening remains critical for early detection.

The American College of Obstetricians and Gynecologists (ACOG) and the American College of Radiology (ACR) recommend that average risk women begin annual screening mammography at age 40. Personal risk factors may affect initiation and types of screening performed.

“Early detection continues to save lives,” says Dr. Szurgot. “For women considering or currently using HRT, it’s important to consistently undergo annual screening and to be aware of their overall breast cancer risk.”

Women with dense breast tissue may benefit from discussing supplemental screening options—such as ultrasound or MRI—with their healthcare provider depending on their risk profile.⁵

Questions Patients Should Ask Their Provider

Patients considering HRT should feel empowered to ask questions, including:

• What type of HRT is being recommended?
• How long is therapy expected to continue?
• How does my personal or family history affect my risk?
• Do I have dense breasts? If HRT leads to dense tissue on a mammogram, should I consider supplemental screening?

Shared decision-making between patients and providers is key to balancing symptom relief with long-term health considerations.

The Bottom Line

Hormone Replacement Therapy can be an effective option for managing menopausal symptoms, but patients should understand both the potential benefits and risks. While some forms of HRT may slightly increase breast cancer risk—particularly with prolonged use of combined hormone therapy—maintaining routine screening and individualized care plans can help support earlier detection and informed health decisions.

At Pinehurst Medical Clinic, we encourage women to stay proactive about their breast health by speaking openly with their providers, understanding their personal risk factors and remaining consistent with recommended screening guidelines.

Sources

1. American Cancer Society — Menopausal Hormone Therapy and Cancer Risk
2. Breastcancer.org — Hormone Replacement Therapy and Breast Cancer Risk
3. UCLA Health — Hormone Therapy and Breast Density Information
4. American College of Obstetricians and Gynecologists (ACOG) — Breast Cancer Risk Assessment and Screening
5. ACR/SBI on average risk screening and guidelines
6. ACR/SBI on high-risk recommendations